GlassScriptPhysician profile
Anil Gungor
NPI 1255581518
$14,674.31
in general payments reported to CMS, 2019-2025
20 companies · $25.93 in 2025
The $25.93 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $175 · 2021: $14K · 2022: $426 · 2024: $221 · 2025: $25.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $13,517.51 | 2020-2021 | |
| Olympus America INC. | $313.24 | 2019-2022 | |
| Optinose US, INC. | $127.65 | 2022 | |
| Shire North American Group INC | $124.47 | 2019 | |
| Depuy Synthes Sales INC. | $120.64 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $119.69 | 2024 | Libtayo |
| Acclarent, INC | $44.31 | 2024 | Acclarent Aera |
| Astrazeneca Pharmaceuticals LP | $39.78 | 2019-2021 | |
| Glaxosmithkline, LLC. | $29.58 | 2019 | |
| Integra Lifesciences Corporation | $29.51 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Biomarin Pharmaceutical INC. | $27.71 | 2024 | Voxzogo 1.2mg |
| Tolmar, INC. | $25.93 | 2025 | Fensolvi |
| Acell, INC. | $25.22 | 2019 | |
| Kaleo, INC. | $23.99 | 2020 | |
| Avanos Medical | $21.26 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $21.08 | 2022 | |
| Pharming Healthcare, INC. | $20.97 | 2019 | |
| Karl Storz Endoscopy-America | $16.64 | 2020 | |
| Covidien LP | $13.16 | 2020 | |
| Boston Scientific Corporation | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Gungor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.